Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL
The salvage therapy in the patients with DLBCL is still controversial. The investigators
conducted this study to evaluate the efficacy and tolerability of Rituximab combined with
ESHAP in the patients with DLBCL. The patients enrolled were defined to be relapsed or
refractory after the first-line chemotherapy like CHOP or other CHOP-like regimens.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
6 weeks
No
Biyun Wang, M.D.
Principal Investigator
Fudan University
China: Ethics Committee
ESHAP-DLBCL
NCT00568815
April 2007
December 2010
Name | Location |
---|